Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs
Coronaviruses (CoVs) are positive-stranded RNA viruses that infect humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKU1 leads to the common cold, short lasting rhinitis, cough, sore throat and fever. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-04-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/9/5/320 |
| _version_ | 1797569595608924160 |
|---|---|
| author | Ujjwal Neogi Kyle J. Hill Anoop T Ambikan Xiao Heng Thomas P. Quinn Siddappa N. Byrareddy Anders Sönnerborg Stefan G. Sarafianos Kamal Singh |
| author_facet | Ujjwal Neogi Kyle J. Hill Anoop T Ambikan Xiao Heng Thomas P. Quinn Siddappa N. Byrareddy Anders Sönnerborg Stefan G. Sarafianos Kamal Singh |
| author_sort | Ujjwal Neogi |
| collection | DOAJ |
| description | Coronaviruses (CoVs) are positive-stranded RNA viruses that infect humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKU1 leads to the common cold, short lasting rhinitis, cough, sore throat and fever. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and the newest SARS-CoV-2 (the causative agent of COVID-19) lead to severe and deadly diseases with mortality rates ranging between ~1 to 35% depending on factors such as age and pre-existing conditions. Despite continuous global health threats to humans, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors. |
| first_indexed | 2024-03-10T20:13:18Z |
| format | Article |
| id | doaj.art-cb1b977b924247ce8fdfac47dc60481e |
| institution | Directory Open Access Journal |
| issn | 2076-0817 |
| language | English |
| last_indexed | 2024-03-10T20:13:18Z |
| publishDate | 2020-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj.art-cb1b977b924247ce8fdfac47dc60481e2023-11-19T22:46:11ZengMDPI AGPathogens2076-08172020-04-019532010.3390/pathogens9050320Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 DrugsUjjwal Neogi0Kyle J. Hill1Anoop T Ambikan2Xiao Heng3Thomas P. Quinn4Siddappa N. Byrareddy5Anders Sönnerborg6Stefan G. Sarafianos7Kamal Singh8Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, 14186 Stockholm, SwedenDepartment of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO 65211, USADivision of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, 14186 Stockholm, SwedenDepartment of Biochemistry, University of Missouri, Columbia, MO 65211, USADepartment of Biochemistry, University of Missouri, Columbia, MO 65211, USADepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Centre, Omaha, NE 68198, USADepartment of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO 65211, USALaboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USADivision of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, 14186 Stockholm, SwedenCoronaviruses (CoVs) are positive-stranded RNA viruses that infect humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKU1 leads to the common cold, short lasting rhinitis, cough, sore throat and fever. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and the newest SARS-CoV-2 (the causative agent of COVID-19) lead to severe and deadly diseases with mortality rates ranging between ~1 to 35% depending on factors such as age and pre-existing conditions. Despite continuous global health threats to humans, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors.https://www.mdpi.com/2076-0817/9/5/320coronavirusSARS-CoVMERS-CoVSARS-CoV-2COVID-19RNA polymerase |
| spellingShingle | Ujjwal Neogi Kyle J. Hill Anoop T Ambikan Xiao Heng Thomas P. Quinn Siddappa N. Byrareddy Anders Sönnerborg Stefan G. Sarafianos Kamal Singh Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs Pathogens coronavirus SARS-CoV MERS-CoV SARS-CoV-2 COVID-19 RNA polymerase |
| title | Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs |
| title_full | Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs |
| title_fullStr | Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs |
| title_full_unstemmed | Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs |
| title_short | Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs |
| title_sort | feasibility of known rna polymerase inhibitors as anti sars cov 2 drugs |
| topic | coronavirus SARS-CoV MERS-CoV SARS-CoV-2 COVID-19 RNA polymerase |
| url | https://www.mdpi.com/2076-0817/9/5/320 |
| work_keys_str_mv | AT ujjwalneogi feasibilityofknownrnapolymeraseinhibitorsasantisarscov2drugs AT kylejhill feasibilityofknownrnapolymeraseinhibitorsasantisarscov2drugs AT anooptambikan feasibilityofknownrnapolymeraseinhibitorsasantisarscov2drugs AT xiaoheng feasibilityofknownrnapolymeraseinhibitorsasantisarscov2drugs AT thomaspquinn feasibilityofknownrnapolymeraseinhibitorsasantisarscov2drugs AT siddappanbyrareddy feasibilityofknownrnapolymeraseinhibitorsasantisarscov2drugs AT anderssonnerborg feasibilityofknownrnapolymeraseinhibitorsasantisarscov2drugs AT stefangsarafianos feasibilityofknownrnapolymeraseinhibitorsasantisarscov2drugs AT kamalsingh feasibilityofknownrnapolymeraseinhibitorsasantisarscov2drugs |